More Xenon Pharmaceuticals Inc. news Xenon Pharmaceuticals Inc.NASDAQ: XENE Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy Oct 4, 2021 · Issued by Xenon Pharmaceuticals Inc. As issuedPlain English Watch Xenon Pharmaceuticals explain it↗Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call · Replay · Aug 6All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of
